1. Design and rationale of the NetherLands registry of invasive Coronary vasomotor Function Testing (NL-CFT).
- Author
-
Crooijmans C, Jansen TPJ, Konst RE, Woudstra J, Appelman Y, den Ruijter HM, Onland-Moret NC, Meeder JG, de Vos AMJ, Paradies V, Woudstra P, Sjauw KD, van 't Hof A, Meuwissen M, Winkler P, Boersma E, van de Hoef TP, Maas AHEM, Dimitriu-Leen AC, van Royen N, Elias-Smale SE, and Damman P
- Subjects
- Humans, Coronary Angiography methods, Netherlands epidemiology, Prospective Studies, Quality of Life, Registries, Coronary Vessels, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease epidemiology
- Abstract
Background: Angina without angiographic evidence of obstructive coronary artery disease (ANOCA) is a highly prevalent condition with insufficient pathophysiological knowledge and lack of evidence-based medical therapies. This affects ANOCA patients prognosis, their healthcare utilization and quality of life. In current guidelines, performing a coronary function test (CFT) is recommended to identify a specific vasomotor dysfunction endotype. The NetherLands registry of invasive Coronary vasomotor Function testing (NL-CFT) has been designed to collect data on ANOCA patients undergoing CFT in the Netherlands., Methods: The NL-CFT is a web-based, prospective, observational registry including all consecutive ANOCA patients undergoing clinically indicated CFT in participating centers throughout the Netherlands. Data on medical history, procedural data and (patient reported) outcomes are gathered. The implementation of a common CFT protocol in all participating hospitals promotes an equal diagnostic strategy and ensures representation of the entire ANOCA population. A CFT is performed after ruling out obstructive coronary artery disease. It comprises of both acetylcholine vasoreactivity testing as well as bolus thermodilution assessment of microvascular function. Optionally, continuous thermodilution or Doppler flow measurements can be performed. Participating centers can perform research using own data, or pooled data will be made available upon specific request via a secure digital research environment, after approval of a steering committee., Conclusion: NL-CFT will be an important registry by enabling both observational and registry based (randomized) clinical trials in ANOCA patients undergoing CFT., Competing Interests: Declaration of Competing Interest NL-CFT is supported by research grants from Dutch Cardiovascular Alliance consortium IMPRESS (2020B004), Philips and Abbott. Damman P received research grants, lecture and consultancy fees from Phillips, and research grants and lecture fees from Abbott Vascular. Van Royen N has received research grants from Philips, Biotronik, Medtronic and Abbott and speaker fees from Microport, Rainmed and Abbott. Van ‘t Hof A received research grants and lecture fees from Abbott Vascular, Medtronic, Boehringer Ingelheim, Astra Zeneca and AMGEN not related to this work. Van de Hoef T received institutional research grants and consultancy fees from Philips and Abbott Vascular. Appelman Y received research grant from Dutch Heart Foundation IMPRESS, lecture and consultancy fees from Abbott Vascular and Phillips. Woudstra P received lecture fees from Philips. All other authors have no disclosures., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF